Trials / Completed
CompletedNCT01222585
Metronidazole Pharmacokinetics (PK) in Premature Infants
Safety and Pharmacokinetics of Multiple Dose Metronidazole in Premature Infants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Michael Cohen-Wolkowiez · Academic / Other
- Sex
- All
- Age
- 90 Days
- Healthy volunteers
- Not accepted
Summary
Yearly in the United States over 500,000 newborns are delivered prematurely. This population is at high risk of catastrophic bowel disease known as necrotizing enterocolitis. Infants with necrotizing enterocolitis are at high risk of death, and survivors are at increased risk of mental retardation. Metronidazole is an antibiotic that is often administered to infants with suspected or confirmed necrotizing enterocolitis. Unfortunately, the appropriate dose of metronidazole in premature infants has not been established and it is likely to be different from older children and adults. The investigators will investigate the appropriate metronidazole dose in very premature infants by: 1) determining how premature infants eliminate metronidazole from the body and 2) determining the safest and most effective dose of metronidazole in premature infants. The investigators hypothesis are: 1) The rate of removal of metronidazole will increase with infant maturity and 2) an appropriate metronidazole dosing regimen will result in necessary drug levels to treat bacteria involved in necrotizing enterocolitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Metronidazole | Metronidazole will be administered intravenously to premature infants as a 15 mg/kg loading dose followed by maintenance doses of 7.5 mg/kg every 12 hours for infants with \>=14 postnatal days and every 24 hours for infants \<14 postnatal days. |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2011-11-01
- Completion
- 2011-11-01
- First posted
- 2010-10-18
- Last updated
- 2014-02-06
- Results posted
- 2013-12-18
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01222585. Inclusion in this directory is not an endorsement.